Onego Bio

Finnish-American startup building a commercial-scale production plant in the US after raising over $40M. Its recombinant egg-white positions itself as a hedge against avian-influenza-driven egg-price volatility.

Country: Finland

Technologies

No articles yet.

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.